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Abstract
International Guidelines for mineral bone disorders recommend that in Non Dialytic-Chronic
Kidney Disease (ND-CKD) clinical decisions should be based on the trend of serum PTH
changes over time rather than on a single value. However, the prognostic impact of these
changes in ND-CKD patients remains unknown. We performed a multicenter cohort study in
ND-CKD patients (stage 1–5) followed for 36 months in 24 Italian Nephrology Units. PTH
changes (ΔPTH) were defined as the absolute differences between all available PTH mea-
surements following the first control and basal value. Primary endpoint in this subanalysis
was renal death (End-Stage Renal Disease (ESRD) or all-causes death before ESRD).
Association between renal death and ΔPTH was assessed by time-dependent Cox model
for repeated measurements. Out of the original cohort (N = 884), we selected 543 patients
(66.3±15.4 ys, 58.4% males) with at least two serum PTH measurements. At baseline,
eGFR was 36 (IQR: 22.4–56.8) mL/min/1.73m2 and serum PTH 46 (IQR: 28–81) pg/mL.
ΔPTH was in median 0 (IQR:-18/18) pg/mL. Basal predictors of longitudinal PTH increments
were higher serum phosphate, more advanced CKD stages and lower serum PTH. Fully
adjusted Cox model with ΔPTH quartiles as discrete time-dependent covariate showed a
significant risk of renal death in the highest quartile (HR: 1.91; 95%CI:1.08–3.38; P = 0.026).
Considering ΔPTH, as continuous time-dependent variable, (HR:1.02; 95%C.I.: 1.01–1.04;
P = 0.004), risk of renal death progressively rose as ΔPTH increased. An increment in
serum PTH over time is associated with a worse prognosis in ND-CKD patients, indepen-
dently from baseline or any absolute concentration of serum PTH and phosphate.
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Introduction
In non-dialysis chronic kidney disease (ND-CKD), serum levels of parathyroid hormone
(PTH) progressively increase since the early stages of disease in order to preserve phosphate
(P) homeostasis [1]. Indeed, nearly 20% of patients with GFR>60 mL/min/1.73m2 have ele-
vated PTH levels that further increase as renal function deteriorates [2–4]. This adaptive mech-
anism modifies renal prognosis as testified by several studies showing a strong association
between high PTH and the risk of faster renal progression [5–8].
Current guidelines, recently updated [9] suggest that medical management of CKD-depen-
dent Mineral Bone Disease (CKD-MBD) should be based on serial measurements of serum
PTH and also therapeutic decisions should be based on trend rather than on a single labora-
tory value. However, this recommendation remains opinion-based being not supported by
any clinical study assessing changes over time of calcium, phosphate or PTH. This is critical
information, considering that fluctuations over time are expected due to either worsening of
renal function or therapeutic interventions, such as dietary phosphate and protein intake
restriction, vitamin D, calcium salts and phosphate binders. It is also important to highlight
that the prognostic studies so far available in ND-CKD patients have examined associations
between secondary hyperparathyroidism and adverse outcome exclusively based on the base-
line serum measurements of MBD parameters and, therefore, not accounting for the changes
over time [5–8].
To fill this gap of knowledge, we performed a prospective analysis in a cohort of patients
with stages 1–5 CKD, regularly followed for 36 months in 24 Italian Nephrology units, and
evaluated the prognostic effect of PTH change over time.
Methods
Study design
This is a multicenter observational prospective cohort study (IRIDE study) performed in
ND-CKD patients afferent to 24 Italian Nephrology units from December 2010 to Septem-
ber 2014. The sample of patients afferent from each participating centre was extremely vari-
able, ranged from 3 to 45 (median:30). The study was approved by Institutional Review
Board and Ethical Committee of each participating center; according to local national regu-
lations (first Ethics Committee approval was granted by the local Ethics Committee of
“Azienda USL 10 di Firenze” on September the 9th 2010). Patients gave written consent to
use their clinical data.
We enrolled adult patients affected by CKD from stage 1 to stage 5, according to criteria of
KDIGO Guidelines [10], followed in the clinic from at least six months. Exclusion criteria
were advanced malignancy, advanced liver or heart failure and renal transplantation.
As described in previous papers [11,12], the sample size of the original cohort (N = 884)
was calculated on the basis of prevalence of secondary hyperparathyroidism, expected to
occur in approximately 40% of patients with stage 4 CKD over a 3-year follow-up period;
patients with stage 4 CKD account for approximately 17% of the sample population on the
basis of an appropriate questionnaire previously completed by participating Nephrology
units. We estimated that 1,000 subjects would have allowed for an estimate of a 95% confi-
dence interval for the frequency of each outcome in the most restrictive condition (50%)
with ±1.6% precision, and that this sample would have allowed to examine also the results
from each CKD stage.
Out of the original IRIDE cohort (N = 884 patients), we selected 543 patients with at least
two measurements of serum PTH within the first year (Fig 1).
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Data collection
According to IRIDE protocol, data were collected in each participating center, starting from
baseline visit, every 6 months, for 36 months (for a maximum of 7 visits). At baseline visit,
Nephrologists collected demographics data, medical history, laboratory test (including pro-
teinuria) and therapy data. The medical history included diagnosis of hypertension according
to K/DIGO guidelines (Systolic BP>130 and/or Diastolic BP>80 with proteinuria and/or dia-
betes) [13] or in antihypertensive treatment with at least one anti-hypertensive drug, diabetes
(either self-reported diagnosis, use of hypoglycemic drugs, or a fasting glucose level>126 mg/
dL), cardiovascular disease (CVD) (defined as electrocardiography-documented angina, his-
tory of myocardial infarction, stroke, transient ischemic attack, intermittent claudication, and
Fig 1. Selection algorithm of patients.
https://doi.org/10.1371/journal.pone.0202417.g001
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prior revascularization procedures) and dyslipidemia (serum Cholesterol>200 mg/dL and/or
use of statin). Laboratory parameters were measured by standard methods in the clinical labo-
ratories of participating centers. Estimated GFR (eGFR) was calculated by the CKD-EPI (CKD
Epidemiology Collaboration) creatinine equation; creatinine was not standardized to isotope-
dilution mass spectrometry values and we therefore reduced creatinine levels by 5%, according
to Skali et al [14].
Serum PTH was measured with the Allegro intact PTH assay from Nichols Institute Diag-
nostics Inc (72.4%). The values of PTH assessed with other method (PTH immunoradiometric
assay by Scantibodies laboratories Inc.) were standardized by equations of the weighted Dem-
ing regression lines [15]. Proteinuria measured using the 24 hour collection (N = 481). Serum
Ca was corrected for albumin levels.
PTH change and outcome
Our aim was to assess the association between change of serum PTH values from baseline and
risk of renal progression. Longitudinal changes of serum PTH were calculated as the absolute
difference between all available PTH values after the first assessment and the basal values
(ΔPTH). In each single patient, the basal value of serum PTH was considered that measured at
the first assessment within the first 12 months of FU. For each subject, ΔPTH was initially
equal to 0 and was updated at each successive PTH assessment.
For example, if the patient had 3 evaluations at baseline and at 6 / 24 and 30 months, respec-
tively equal to 100, 100, 120 and 70pg/mL, our variable of interest (ΔPTH) was 0 for six
months, +20 in the following 18 months and -30 until end of follow up. Therefore for this
patient, three ΔPTH (0, +20 and -30) and corresponding intervals (6, 18 and 6 months) were
taken into account in the models.
Primary outcome in this sub-analysis was renal death, defined as a composite endpoint
including ESRD (chronic dialysis or pre-emptive kidney transplantation) or all-cause death
before ESRD, whichever occurred first. Patients were followed up from the day of baseline visit
until September 30, 2014 ESRD or death before ESRD or for lost to follow-up censored on the
date they had the last clinic visit. Local investigators contacted by phone patients missing two
or more planned visits to ascertain vital status and start of ESRD. This latter event was subse-
quently confirmed by Regional Dialysis Registries.
Statistics
Continuous variables were reported as either mean and standard deviation (SD) or median
and interquartile range (IQR) according to their distribution (assessed by using Shapiro-Wilk
test). Intergroup comparisons were performed by means of one-way analysis-of-variance or
Kruskal-Wallis test, as appropriate. Categorical variables were expressed as percentages and
compared by Chi-square test. To examine changes over time of laboratory values, we used a
within-subjects ANOVA test, whereas for non-parametric variables we assessed the changes
using Skillings–Mack test, that is a general Friedman-type statistic that can be used in almost
any block design with an arbitrary missing-data structure [16].
A Generalized Linear Mixed Model with both fixed and random effects was fitted in order
to assess which baseline variables were associated with changes of serum PTH over time
(ΔPTH), using the compound symmetric as covariance structure, i.e. assuming that there is a
correlation among separate measurements and that the correlation is constant regardless of
how far apart the measurements are [17].
To estimate the role of baseline PTH and its longitudinal changes over time on the renal
death multivariable Cox proportional hazards model was used to estimate hazard ratio (HR)
Prognosis of serum PTH changes in CKD
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and 95% confidence interval (CI). Model was adjusted for baseline covariates (age, gender, dia-
betes, prior CV disease, hypertension, RAS inhibitors, serum total calcium and phosphate,
PTH and proteinuria) identified a priori as possible confounders and stratified by CKD stages
and cohort dimension. Then, we performed a model with the same baseline covariates, but
adding ΔPTH, as both continuous and discrete (ΔPTH quartiles) time-varying dependent
covariates. Indeed Cox model allows to analyze covariate information that change over time,
with the hazard proportional to the instantaneous probability of an event at a particular time
[18].
To analyze non-linear association between continuous ΔPTH and renal death restricted
cubic spline according to Harrell method was used [19].
A two-tailed P value <0.05 was considered significant. Data were analyzed using STATA
11.2 (College Station, Texas USA).
Results
As illustrated in Fig 1, 543 patients were included into the analysis and 341 patients were
excluded. Of note, the incidence rate of renal death in those patients excluded from this analy-
sis were not different than those included, respectively 6.4 (CI 95%: 4.9–8.2) events per 1000
person-year vs 6.3 (CI 95%: 5.2–7.6) events per 1000 person-year (P = 0.940).
Demographic and clinical characteristics stratified by CKD stage are illustrated in Table 1.
Briefly, whole population (all white) was characterized by advanced age (46.8% of patients
were aged 65–80 years and 15.5% over 80 years). Males were the majority of the population
(58.4%). At baseline, eGFR was in median 36 (IQR: 22.4–56.8) mL/min/1.73 m2 and protein-
uria was 0.4 (0.1–1.1) mg/24h. The distribution by CKD stages was 21% in stage 1–2, 17% in
stage 3a, 22% in stage 3b, 28% in stage 4 and 12% in stage 5. As expected, from earlier to more
advanced stages of CKD, prevalence of hypertension, anemia and CVD progressively increased
as the serum levels of PTH and phosphate. Hypertensive patients were all treated with at least
one anti-hypertensive drug.
Pharmacologic treatment of CKD-MBD over CKD stages at baseline are reported in
Table 2. Notably, prescription of nutritional Vitamin D did not change across CKD stages,
whereas use of activated vitamin D progressively increased up to 4-fold from earlier to
advanced CKD stages. Similarly, the use of calcium salt and non-calcium containing
Table 1. Demographics and basal clinic features of study cohort overall and by CKD stage.
Overall Stage 1–2 Stage 3a Stage 3b Stage 4 Stage 5 P
Number (%) 543 (100) 115 (21.2) 92 (16.9) 117 (21.6) 151 (27.8) 68 (12.5)
GFR-EPI (mL/min/1.73 m2) 36(22–57) 75(67–93) 51(48–55) 36(32–41) 23(19–26) 12(10–15)
Age (years) 66.3±15.4 56.9±17.8 69.7±9.5 69.7±11.7 69.6±13.3 64.5±15.4 <0.0001
Male gender (%) 58.4 59.1 59.8 61.5 58.9 48.5 0.506
Diabetes (%) 27.8 24.4 33.7 28.2 29.8 20.6 0.361
CVD (%) 23.8 9.6 28.3 20.5 31.8 29.4 <0.0001
Dyslipidemia (%) 41.6 34.8 42.4 41.0 45.7 44.1 0.322
Hypertension (%) 93.7 87.0 92.4 95.7 96.7 97.1 0.009
ACEi and/or ARBs (%) 54.0 63.5 55.5 56.4 56.3 26.5 <0.0001
Anemia (%) 26.9 3.5 10.9 17.1 40.4 75.0 <0.0001
Proteinuria (g/day) 0.4 (0.1–1.1) 0.2 (0.1–0.9) 0.2 (0.0–0.4) 0.3 (0.1–0.9) 0.5 (0.2–1.1) 0.7 (0.4–1.5) <0.0001
Serum Total Calcium (mg/dL) 9.3±0.6 9.3±0.5 9.4±0.5 9.3±0.5 9.2±0.6 9.2±0.6 0.061
Serum Phosphate (mg/dL) 3.7±0.8 3.4±0.6 3.3±0.7 3.3±0.5 3.9±0.7 4.5±0.9 <0.0001
Serum PTH (pg/mL) 46 (28–81) 28 (18–39) 38 (26–55) 46 (35–67) 63 (43–102) 90 (54–151) <0.0001
https://doi.org/10.1371/journal.pone.0202417.t001
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phosphate binders (lanthanum carbonate and sevelamer) increased with advancing of renal
disease.
Survival analysis
During follow-up (median 36 months IQR: 33–37 months), no significant difference in serum
levels of PTH was detected (p = 0.08). In these patients we registered a reduction of eGFR
(p<0.0001) and a raise of serum phosphate (p<0.0001) in the absence of changes of serum cal-
cium. ΔPTH over time was in median 0 (IQR: -18/18) pg/mL. The generalized linear mixed
model showed that higher serum phosphate, CKD stages 3b-5 and lower serum PTH at base-
line were associated with an increased risk to have a positive ΔPTH over time (Table 3).
During follow-up we registered 114 renal deaths (82 ESRD events, all initiation of chronic
dialysis, and 32 overall-cause deaths before ESRD). Incidence rates were 4.5 per 1000 patient
year (95% CI, 3.6 to 5.6) for ESRD and 1.8 per 1000 patient-year (95% CI, 1.3 to 2.6) for death
before ESRD.
Table 2. Therapeutic features of CKD-MBD of study cohort, overall and by CKD stage, at baseline.
Overall Stage1-2 Stage 3a Stage 3b Stage 4 Stage 5 P
Cholecalciferol (%) 16.4 20.0 19.6 15.4 16.7 7.4 0.206
Vitamin D analogue (%) 46.6 20.0 32.6 43.4 62.9 79.4 <0.0001
Calcidiol(%) 1.6 0 0 3.9 1.1 1.9
Calcifediol(%) 21.8 47.8 43.3 23.5 15.8 7.4
Calcitriol (%) 57.3 39.1 36.7 62.7 60.0 66.7
Paracalcitol(%) 19.4 13.0 20.0 9.8 23.2 24.1
Calcium supplement (%) 17.7 10.4 4.4 13.7 25.2 38.3 <0.0001
Non-Calcium-Phosphate binders (%) 5.7 0 0 0.9 8.6 26.5 <0.0001
Aluminium based (%) 1.4 0 0 0.9 4.6 8.8
Sevelamer (%) 2.6 0 0 0 2.0 11.8
Lanthanium (%) 1.8 0 0 0 2.0 6.0
https://doi.org/10.1371/journal.pone.0202417.t002
Table 3. Basal predictors of change over time in serum PTH (ΔPTH) by general linear mixed model.
Beta (C.I. 95%) P
Time (months) 0.06 (-0.38; 0.24) 0.673
Age (years) 0.12 (-0.24; 0.48) 0.517
Male gender (yes vs no) 4.87 (-5.0; 14.75) 0.333
Diabetes (yes vs no) 7.40 (-3.19; 17.98) 0.171
CKD stage 1–2 Ref
Stage 3a 3.93 (-11.87;19.73) 0.626
Stage 3b 15.35 (0.64; 30.06) 0.041
Stage 4 35.14 (19.78–50.49) <0.0001
Stage 5 58.95 (38.12–79.79) <0.0001
Hypertension (yes vs no) 1.64 (-18.7; 22.0) 0.874
Prior CVD (yes vs no)) 7.28 (-4.49; 19.05) 0.225
Serum Phosphate (mg/dL) 10.09 (2.78;17.40) 0.007
Serum total Calcium (mg/dL) -6.35(-14.89; 2.19) 0.145
Serum PTH (pg/mL) -0.38 (-0.43;-0.33) <0.0001
Proteinuria (mg/day) 1.44 (-2.98; 5.85) 0.523
Constant 34.5 (-52.87; 121.91) 0.439
https://doi.org/10.1371/journal.pone.0202417.t003
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Cox analysis showed that basal serum levels of PTH and phosphate and proteinuria were
main modifiable predictors of renal death (Model 1 in the Table 4). When we added to the
model containing baseline variables ΔPTH quartiles (Model 2 in Table 4), as discrete time-
varying covariate, we found a graded association with the risk of renal death that became sig-
nificant for the highest ΔPTH quartile (>18 pg/mL; P = 0.026).
The importance of PTH changes over time was confirmed when using ΔPTH as continuous
time dependent variable. Restricted cubic spline with four knots showed that HR for renal
death increased in a linear fashion with the increment in ΔPTH (Fig 2; P value for non-linear
association: 0.805) and linear ΔPTH was significantly associated with renal death (HR:1.02; C.
I.:1.01–1.04 for every 10 pg/mL; p = 0.004).
We performed a sensitivity analysis by excluding CKD stage 1–2 from Cox analysis. In this
sub cohort (N = 428 patients), the risk for renal death was not different from that observed in
whole cohort (HR:1.04; C.I.:1.02–1.06 for every 10 pg/mL; p<0.001). Finally, we performed a
further sensitivity analysis showing that ΔPTH was independently associated with ESRD alone
(HR for ESRD: 1.02 95% C.I.: 1.00–1.04; P = 0.019).
Discussion
In a cohort of 543 patients in stage 1–5 CKD regularly followed in 24 Italian Nephrology units
we found that serum increment over time of PTH heralds worst renal outcome. More specifi-
cally, we examined the association between renal death and the longitudinal changes within
the same subject of serum PTH with respect to baseline value (ΔPTH). In particular, we
observed that risk progressively rose, as ΔPTH increased, independently from the well-known
cardio-renal risk factors related to CKD.
These findings are relevant for two main reasons. First, in ND-CKD patients serum PTH
may change frequently due to the deterioration of kidney function over time and unmodified
phosphate intake, as GFR deteriorates. In fact, to maintain homeostasis of phosphate, renal
function of the diseased kidney must undergo adaptive changes, through the decrement in
Table 4. Cox Analysis of determinants of renal death adjusted for baseline covariates (model 1) and adding time varying covariate (model 2: Model 1 + delta PTH)
stratified by CKD stage and cohort dimension.
Model 1 Model 2
Hazard Ratio (95% C.I:) P Hazard Ratio (95% C.I.) P
Age (years) 1.01 (0.99–1.03) 0.420 1.01 (0.99–1.03) 0.447
Males vs Females 1.92 (1.17–3.13) 0.010 1.90 (1.16–3.12) 0.010
Diabetes Yes vs No 1.21 (0.75–1.96) 0.445 1.25 (0.77–2.03) 0.373
CVD Yes vs No 1.83 (1.15–2.92) 0.011 1.86(1.17–2.96) 0.009
Hypertension Yes vs No 0.88 (0.20–3.87) 0.855 0.88 (0.20–3.88) 0.866
RAS inhibitors Yes or No 0.81 (0.49–1.32) 0.409 0.72 (0.44–1.20) 0.219
Proteinuria (+1 g/day) 1.35 (1.14–1.61) 0.001 1.31 (1.10–1.55) 0.002
Serum Total Calcium (+1 mg/dL) 0.84 (0.57–1.25) 0.388 0.87 (0.59–1.28) 0.465
Serum Phosphate (+1 mg/dL) 1.46 (1.07–1.98) 0.015 1.39 (1.03–1.89) 0.035
Serum PTH (+10 pg/ml) 1.03 (1.01–1.04) <0.0001 1.04 (1.02–1.05) <0.0001
ΔPTH quartiles
< -18
-18 to 0
0 to 18
>18 pg/mL
-
-
-
-
Ref.
1.09 (0.47–2.55)
1.70 (0.74–3.89)
1.91 (1.08–3.38)
-
0.820
0.201
0.026
RAS, Renin Angiotensin System
https://doi.org/10.1371/journal.pone.0202417.t004
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tubular reabsorption of phosphate, that prevent a rise in the serum phosphate until advanced
deterioration of renal function occurs [1]. However, as Bricker proposed in his “trade-off
hypothesis" [20], a biologic price is paid for these adaptive changes, with the development of
secondary hyperparathyroidism that is mainly caused by phosphate retention. Furthermore,
nephrologists’ management of CKD-MBD includes the implementation of low protein and
phosphate diet and the use of drugs, such as analogues of vitamin D, phosphate binders and
calcium salt, that affects greatly serum PTH. Because our study was carried out in tertiary care,
this aspect becomes essential, as evidenced by large use of CKD-MBD therapeutic agents at
baseline (Table 2).
In a similar scenario, the use of statistical methods for time-to-event data that can incorpo-
rate time-dependent covariates is mandatory [21]. In particular, time-dependent Cox models
represent a more appropriate tool to evaluate the longitudinal prognosis in chronic patients,
since this model offers the opportunity to associate changes in exposure over time (time vary-
ing covariate) with outcome. Therefore this model can properly answer the critical question
on how longitudinal changes in serum PTH versus baseline can affect the prognosis [22,23].
Fig 2. Plot of adjusted hazard ratio and 95% confidence intervals (as indicated by the curvilinear dash lines; the horizontal lines represent HR = 1) for renal death
by level of ΔPTH as continuous variable (reference level, 0 pg/mL).
https://doi.org/10.1371/journal.pone.0202417.g002
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To our knowledge, this is the first time that this statistical method was used to assess the
effect of longitudinal PTH changes in ND-CKD patients. A similar method was used by
Kalanthar-Zadeh et al. in a cohort of about 58,000 patients on maintenance HD [23]. Those
authors examined the associations between survival and changes in blood concentrations of
quarterly mean PTH (as 8 categories: <100,>700 pg/mL and six 100 pg/mL groups in-
between), using either time-dependent Cox models with repeated measures or fixed-covariate
Cox models with only baseline values [23]. We have similarly examined the effect on renal
death of fixed covariates measured at baseline and then adding ΔPTH, as both continuous and
discrete (quartiles) time-dependent covariate.
When we considered fixed covariates measured at baseline, we found that higher serum
PTH associated with an increased risk of renal death, as already reported in diverse ND-CKD
cohorts, [5–8, 24–31]. The novel finding of our study is that when time-varying ΔPTH was
added into the model, the longitudinal increment of serum PTH acted as a predictor of renal
death independent of basal fixed covariate, i.e. older age, CKD stage, serum levels of PTH and
phosphate, and, more important, independently from proteinuria, that is considered the main
risk factor of CKD progression [32].
Noteworthy, we found that an increment of serum PTH over time was predicted by elevated
levels of serum phosphate and more advanced CKD stages. These findings are consistent with
pathogenic hypothesis that higher levels of serum phosphate stimulates directly the PTH secre-
tion, as GFR decreases [33]. Furthermore, as previously reported, serum PTH levels rose from
stage 1–2 to stage 5 [2–4]. Nevertheless early alterations of serum PTH are seldom detected at
these stages of CKD and no recommendations are given for its management and prevention
[9]. Indeed, we did not register any outcome in earlier stages suggesting that at these levels of
CKD the effect on renal prognosis is probably of minor entity, as confirmed by sensitivity anal-
ysis in a sub-cohort of patients with GFR < 60 mL/min/1.73 m2. However, the relatively low
number of renal outcomes in our study may be consequent to a limited follow up; indeed, pre-
vious work in a large community without renal insufficiency has reported that elevated plasma
levels of PTH can account for 20% of the population-attributable risk proportion for CV mor-
tality, indicating that elevated serum PTH may have a significant prognostic effect even in the
absence of renal dysfunction [34].
Noteworthy, CKD patients with low and stable PTH levels may have Adynamic Bone Dis-
ease (ABD), that is associated with higher CV risk possibly dependent on increased vascular
calcifications [35]. This is in apparent contrast with our findings. However, ABD is more com-
mon in dialysis patients, especially in those with advanced age, diabetes and undergoing high
calcium load. On the other hand, low rate of death observed in the 3 years of FU did not allow
to assess adequately this specific issue.
This study has several limitations. First, the observational design does not allow an interpre-
tation of results in causal terms and we cannot draw any conclusion about the role of treatment
on the PTH change. Second, we cannot generalize our findings to unreferred patients or to
ethnic groups other than Caucasians. However the criteria to select CKD patients in stages 1–5
from Nephrology units distributed over almost the entire Italian territory, may be considered
representative of Italian CKD population. Third, we cannot exclude survival bias that may be
present in referred cohorts and selection bias (we excluded about 38% of original cohort);
though incidence rates of renal death of patients excluded were not different than those
included into the present analysis. Fourth, the cohort is made for 63% of elderly patients (>65
years) that may greatly affect the renal prognosis of these patients [30]; however, this cohort is
a real picture of CKD population referred to nephrologists [29–31]. Finally, data on protein
and phosphate intake were not collected [36].
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In conclusion, the increment in serum PTH over 36 months represents an independent risk
factor for renal death in ND-CKD patients. This finding provides a formal support to current
guidelines that indicate the need of repeated measurements of serum PTH to better stratify the
risk of CKD patients. Our data also highlight the importance of implementation in Nephrology
research of statistical models with time dependent covariates in order to better define the prog-
nosis of CKD patients [37]
Supporting information
S1 dataset. Complete dataset.
(XLSX)
Author Contributions
Conceptualization: Silvio Borrelli, Michele Provenzano, Carlo Garofalo, Giuseppe Remuzzi,
Anna Maria Costanzo, Giuseppe Conte.
Data curation: Michele Provenzano, Giuliana Gualberti.
Formal analysis: Silvio Borrelli, Paolo Chiodini, Michele Provenzano.
Funding acquisition: Anna Maria Costanzo.
Methodology: Silvio Borrelli, Paolo Chiodini, Michele Provenzano, Giuliana Gualberti.
Project administration: Anna Maria Costanzo, Giuliana Gualberti.
Supervision: Paolo Chiodini, Luca De Nicola, Roberto Minutolo, Carlo Garofalo, Giuseppe
Remuzzi, Claudio Ronco, Mario Gennaro Cozzolino, Carlo Manno, Giuseppe Conte.
Writing – original draft: Silvio Borrelli, Luca De Nicola, Roberto Minutolo, Carlo Garofalo,
Giuseppe Remuzzi, Claudio Ronco, Giuseppe Conte.
References
1. Ritter CS, Slatopolsky E (2016). Phosphate Toxicity in CKD: The Killer among us. Clin J Am Soc
Nephrol; 11(6):1088–100. https://doi.org/10.2215/CJN.11901115 PMID: 26912542
2. Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA et al (2007). Prevalence of abnormal
serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the
study to evaluate early kidney disease. Kidney Int 71:31–8. https://doi.org/10.1038/sj.ki.5002009
PMID: 17091124
3. Craver L, Marco MP, Martinez I, Rue M, Borràs M, Martı´n ML, et al (2007). Mineral metabolism parame-
ters throughout chronic kidney disease stages 1–5: achievement of K/DOQI target ranges. Nephrol Dial
Transpl 22:1171–6
4. Moranne O, Froissart M, Rossert J, Gauci C, Boffa JJ, Haymann JP et al (2009). Timing of onset of
CKD-related metabolic complications. J Am Soc Nephrol 20:164–71. https://doi.org/10.1681/ASN.
2008020159 PMID: 19005010
5. Kovesdy CP, Ahmadzadeh S, Anderson JE, Kalantar-Zadeh K (2008). Secondary hyperparathyroidism
is associated with higher mortality in men with moderate to severe chronic kidney disease. Kidney Int.;
73(11):1296–1302. https://doi.org/10.1038/ki.2008.64 PMID: 18337714
6. Chartsrisak K, Vipattawat K, Assanatham M, Nongnuch A, Ingsathit A, Domrongkitchaiporn S et al.
(2013). Mineral metabolism and outcomes in chronic kidney disease stage 2–4 patients. BMC Nephrol.;
14:14; 2369–14.
7. De Boer IH, Gorodetskaya I, Young B, Hsu CY, Chertow GM (2002). The severity of secondary hyper-
parathyroidism in chronic renal insufficiency is GFR-dependent, race-dependent, and associated with
cardiovascular disease. J Am Soc Nephrol ; 13(11):2762–9. PMID: 12397047
8. De Nicola L, Conte G, Chiodini P, D’Angiò P, Donnarumma G, Minutolo R (2014). Interaction between
phosphorus and parathyroid hormone in non-dialysis CKD patients under nephrology care. J Nephrol.;
27(1):57–63. https://doi.org/10.1007/s40620-013-0001-8 PMID: 24519864
Prognosis of serum PTH changes in CKD
PLOS ONE | https://doi.org/10.1371/journal.pone.0202417 August 23, 2018 10 / 12
9. Ketteler M, Block GA, Evenepoel P, Fukagawa M, Herzog CA, McCann L et al. (2017). Executive sum-
mary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline
Update: what’s changed and why it matters Kidney Int 92; 26–36. https://doi.org/10.1016/j.kint.2017.
04.006 PMID: 28646995
10. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group (2013). KDIGO 2012 Clinical
Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int 3: S1–
S150.
11. Jommi C, Armeni P, Battista M, di Procolo P, Conte G, Ronco C, et al. (2017) The Cost of Patients with
Chronic Kidney Failure Before Dialysis: Results from the IRIDE Observational Study. Pharmacoecon
Open. PharmacoEconomics-open, 1–9. https://doi.org/10.1007/s41669-016-0009-9
12. Cozzolino M, Bolasco P, Ronco C, Conte G, Menè P, Mereu MC et al. (Published online ahead of print
on July 17, 2018) Nephron Clinical Practice, Clinical Management of Chronic Kidney Disease Patients
in Italy: Results from the IRIDE Study Nephron (https://doi.org/10.1159/000490769)
13. Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO Clinical
Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int Suppl.
2012; 2:337–414.
14. Skali H, Uno H, Levey AS, Inker LA, Pfeffer MA, Solomon SD (2011). Prognostic assessment of esti-
mated glomerular filtration rate by the new Chronic Kidney Disease Epidemiology Collaboration equa-
tion in comparison with the Modification of Diet in Renal Disease Study equation. Am Heart J.; 162(3):
548–554 https://doi.org/10.1016/j.ahj.2011.06.006 PMID: 21884875
15. Souberbielle JC, Boutten A, Carlier MC, Chevenne D, Coumaros G, Lawson-Body E et al. (2006). Inter-
method variability in PTH measurement: implication for the care of CKD patients. Kidney Int.; 70
(2):345–50. https://doi.org/10.1038/sj.ki.5001606 PMID: 16788691
16. Chatfield M, Mander A (2009). The Skillings-Mack test (Friedman test when there are missing data).
Stata J; 9(2):299–305. PMID: 19829764
17. Graubard BI, Korn EL (1996). Modelling the sampling design in the analysis of health surveys. Stat
Methods Med Res; 5(3):263–81. https://doi.org/10.1177/096228029600500304 PMID: 8931196
18. Kalbfleisch JD, Prentice RL (1980). The Statistical Analysis of Failure Time Data. New York, NY: John
Wiley.
19. Harrell FE Jr, Lee KL, Pollock BG (1988). Regression models in clinical studies: determining relation-
ships between predictors and response. J Nat Cancer Inst.; 80(15):1198–202. PMID: 3047407
20. Bricker NS (1972): On the pathogenesis of the uremic state. An exposition of the “trade-off hypothesis”.
N Engl J Med; 286: 1093–9. https://doi.org/10.1056/NEJM197205182862009 PMID: 4553202
21. Bellera CA, MacGrogan G, Debled M, de Lara CT, Brouste V, Mathoulin-Pe´lissier S (2010). Variables
with time-varying effects and the Cox model: some statistical concepts illustrated with a prognostic fac-
tor study in breast cancer. BMC Med Res Methodol. Mar 16; 10:20. https://doi.org/10.1186/1471-2288-
10-20 PMID: 20233435
22. Barbour SJ, Cattran DC, Espino-Hernandez G, Hladunewich MA, Reich HN (2015). Identifying the ideal
metric of proteinuria as a predictor of renal outcome in idiopathic glomerulonephritis. Kidney Int.; 88
(6):1392–401. https://doi.org/10.1038/ki.2015.241 PMID: 26287314
23. Kalantar-Zadeh K, Kuwae N, Regidor DL, Kovesdy CP, Kilpatrick RD, Shinaberger CS et al. (2006).
Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients.
Kidney Int; 70: 771–80. https://doi.org/10.1038/sj.ki.5001514 PMID: 16820797
24. Kestenbaum B, Sampson JN, Rudser KD, Patterson DJ, Seliger SL, Young B et al (2005). Serum phos-
phate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 16:520–8.
https://doi.org/10.1681/ASN.2004070602 PMID: 15615819
25. Schwarz S, Trivedi BK, Kalantar-Zadeh K, Kovesdy CP (2006) Association of disorders in mineral
metabolism with progression of chronic kidney disease. Clin J Am Soc Nephrol 1:825–31. https://doi.
org/10.2215/CJN.02101205 PMID: 17699293
26. Voormolen N, Noordzij M, Grootendorst D, Beetz I, Sijpkens YW, van Manen JG et al (2007). High
plasma phosphate as a risk factor for decline in renal function and mortality in pre-dialysis patients.
Nephrol Dial Transpl 22:2909–16
27. Eddington H, Hoefield R, Sinha S, Chrysochou C, Lane B, Foley RN et al. (2010). Serum phosphate
and mortality in patients with chronic kidney disease. Clin J Am Soc Nephrol; 5:2251–7. https://doi.org/
10.2215/CJN.00810110 PMID: 20688884
28. Bellasi A, Mandreoli M, Baldrati L, Corradini M, Di Nicolò P, Malmusi G et al. (2011). Chronic kidney dis-
ease progression and outcome according to serum phosphorus in mild-to-moderate kidney dysfunction.
Clin J Am Soc Nephrol; 6:883–91 https://doi.org/10.2215/CJN.07810910 PMID: 21393493
Prognosis of serum PTH changes in CKD
PLOS ONE | https://doi.org/10.1371/journal.pone.0202417 August 23, 2018 11 / 12
29. De Nicola L, Chiodini P, Zoccali C, Borrelli S, Cianciaruso B, Di Iorio B et al (2011). Prognosis of CKD
patients receiving outpatient nephrology care in Italy. Clin J Am Soc Nephrol 6:2421–28. https://doi.org/
10.2215/CJN.01180211 PMID: 21817127
30. De Nicola L, Minutolo R, Chiodini P, Borrelli S, Zoccali C, Postorino M et al for Italian Society of Nephrol-
ogy Study Group Target Blood pressure Levels (TABLE) in CKD (2012). The effect of increasing age on
the prognosis of non-dialysis patients with chronic kidney disease receiving stable nephrology care. Kid-
ney Int.; 82(4):482–8. https://doi.org/10.1038/ki.2012.174 PMID: 22622495
31. De Nicola L, Provenzano M, Chiodini P, Borrelli S, Garofalo C, Pacilio M et al (2015). Independent Role
of Underlying Kidney Disease on Renal Prognosis of Patients with Chronic Kidney Disease under
Nephrology Care. PLoS One. May 20; 10(5).
32. Astor BC, Matsushita K, Gansevoort RT, van der Velde M, Woodward M, Levey AS, Jong PE, Coresh
J; Chronic Kidney Disease Prognosis Consortium (2011). Lower estimated glomerular filtration rate and
higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-
analysis of kidney disease population cohorts. Kidney Int. Jun; 79(12):1331–40. https://doi.org/10.1038/
ki.2010.550 PMID: 21289598
33. Slatopolsky E, Brown A, Dusso A. (1999). Pathogenesis of secondary hyperparathyroidism. Kidney Int
Suppl. Dec; 73:S14–9. PMID: 10633458
34. Hagstro¨m E, Hellman P, Larsson TE, Ingelsson E, Berglund L, Sundstro¨m J et al. (2009) Plasma para-
thyroid hormone and the risk of cardiovascular mortality in the community. Circulation; 119(21):2765–
71. https://doi.org/10.1161/CIRCULATIONAHA.108.808733 PMID: 19451355
35. Brandenburg VM, Floege J. Adynamic bone disease-bone and beyond. NDT Plus. 2008 Jun; 1(3):135–
47. https://doi.org/10.1093/ndtplus/sfn040 PMID: 25983860
36. Bellizzi V, Cupisti A, Locatelli F, Bolasco P, Brunori G, Cancarini G et al. “Conservative Treatment of
CKD” study group of the Italian Society of Nephrology. Low-protein diets for chronic kidney disease
patients: the Italian experience. BMC Nephrol.; 17(1):77. https://doi.org/10.1186/s12882-016-0280-0
37. Greene T and Li L(2017). From Static to Dynamic Risk Prediction: Time Is Everything. Am J Kidney Dis. ;
69(4): 492–4. https://doi.org/10.1053/j.ajkd.2017.01.004 PMID: 28340850
Prognosis of serum PTH changes in CKD
PLOS ONE | https://doi.org/10.1371/journal.pone.0202417 August 23, 2018 12 / 12
